Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002514 · ClinicalTrials.gov registry record · Phase 3
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,929
- Enrollment target
NCT00002514: Completed Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
NCT00002514 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 1,929 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (150% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002514, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,929 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
Interventions
- DRUG cyclophosphamide
- DRUG cytarabine
- BIOLOGICAL sargramostim
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,929 participants |
| Start Date | 1993-05-07 |
| Phase | Phase 3 |
What the finished NCT00002514 record still lists
NCT00002514 is an interventional study that assigns participants to a tested intervention. Its 1,929 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (150% higher).
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002514 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002514 about?
NCT00002514 is a clinical study titled "Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission". RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It i...
What is the current status of trial NCT00002514?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,929 participants. The study started on 1993-05-07.
What interventions are being tested in trial NCT00002514?
The interventions under investigation include: cyclophosphamide (DRUG), cytarabine (DRUG), sargramostim (BIOLOGICAL), asparaginase (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002514?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002514's enrollment target sits among peer trials
1,929 109th of 2000 higher than 1,892 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06799117 · 1,912 participants · NA
Adaptive Decision Support for Addiction Treatment Master
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI